Federated Hermes Inc. Has $76.55 Million Holdings in Illumina, Inc. $ILMN

Federated Hermes Inc. trimmed its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 802,343 shares of the life sciences company’s stock after selling 4,416 shares during the period. Federated Hermes Inc. owned approximately 0.52% of Illumina worth $76,552,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Parkside Financial Bank & Trust lifted its holdings in Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after buying an additional 115 shares in the last quarter. Rise Advisors LLC raised its position in shares of Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 224 shares during the last quarter. Cullen Frost Bankers Inc. bought a new stake in shares of Illumina during the second quarter worth $41,000. NewSquare Capital LLC lifted its stake in shares of Illumina by 604.9% during the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after acquiring an additional 369 shares during the period. Finally, Evelyn Partners Investment Management LLP boosted its holdings in Illumina by 4,927.3% in the second quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock valued at $49,000 after acquiring an additional 542 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 0.7%

ILMN opened at $128.96 on Monday. The firm’s fifty day moving average is $111.21 and its two-hundred day moving average is $101.07. The firm has a market cap of $19.71 billion, a PE ratio of 28.91, a price-to-earnings-growth ratio of 2.31 and a beta of 1.44. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $153.06. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The firm’s quarterly revenue was up .4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of research reports. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Daiwa America lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 12th. Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 2nd. Robert W. Baird set a $109.00 target price on shares of Illumina in a research report on Friday, October 31st. Finally, Royal Bank Of Canada set a $124.00 price target on Illumina in a research note on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $115.00.

Insider Activity at Illumina

In other Illumina news, Director Scott Gottlieb acquired 500 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were acquired at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the acquisition, the director directly owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This trade represents a 4.16% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.